<DOC>
	<DOCNO>NCT00192205</DOCNO>
	<brief_summary>- Trial compare efficacy liquid formulation CAIV-T TIV culture confirm influenza illness child .</brief_summary>
	<brief_title>Trial Compare Safety , Tolerability Efficacy Influenza Virus Vaccine , ( CAIV-T ) With Influenza Virus Vaccine , Trivalent , Inactivated ( TIV ) Children</brief_title>
	<detailed_description>- The purpose study compare efficacy liquid formulation CAIV-T TIV culture confirm influenza illness child history recurrent RTIs age least 6 month le 72 month age . - The trial also provide opportunity compare efficacy CAIV-T TIV acute otitis medium .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>age least 6 month le 72 month age time enrolment ; experience two practitioner attend RTIs* past 12 month ( since birth le 12 month old ) ; * RTIs define upper RTIs include ( limited ) common cold , acute otitis medium low RTIs include ( limited ) bronchiolitis , bronchitis pneumonia . whose parent ( ) /legal guardian ( ) provide write informed consent nature study explain ; , along parent ( ) /legal guardian ( ) , available duration trial ; whose parent ( ) /legal guardian ( ) , reach study staff postvaccination contact [ telephone , clinic home visit ] . whose parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period ; serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease ; Down 's syndrome know cytogenetic disorder ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid dose equivalent ( ) 2mg/kg/day great Prednisolone ( ii ) equivalent total 20 mg/day great child weigh 10kg , 14 day duration 2 week corticosteroid discontinue 27 ; receive blood product , include immunoglobulin , period six month prior vaccination conclusion study ; intent administer investigational vaccine agent one month prior enrolment conclusion study ; immunosuppressed immunocompromised individual living household ; , time prior entry study , receive dose influenza vaccine ( commercial investigational ) anticipate receive nonstudy influenza vaccine enrollment ; document history hypersensitivity egg egg protein component CAIVT TIV ; receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior enrolment use anticipate study ; medical condition opinion investigator might interfere interpretation study result ; Note : Pregnancy person regular contact subject contraindication enrolment ongoing participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>